Myricx Bio Secures £90 Million Series A Funding to Revolutionize Cancer Treatment with Novel NMTi-ADC Therapeutics
A new wave of hope is washing over the oncology field with Myricx Bio’s impressive £90 million ($114 million) Series A funding. This UK biotech company, unlike its peers, isn’t taking an incremental step forward. Instead, they’re wielding a whole new weapon in the fight against cancer: N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugates (ADCs). The significance…